In addition, when the cutoff for apoA2-ATQ/AT (apoA2-i Index) was defined as 59.5 μg/mL according to the prespecified criterion, the sensitivities of apoA2-ATQ/AT for stage I and TS1 of pancreatic cancer were 47.4% and 46.7%, respectively, and both of these sensitivities were higher than those of CA19-9. The gene discussed is APOA2; the disease is pancreatic neoplasm.